[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356218-105":59,"doc-detail-356218-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-aif-to-trigger-ripksmlkl-necroptosis-a-disulfiram-based-strategy-to-reverse-paclitaxel-resistance-in-ovarian-cancer","Targeting AIF to trigger RIPKs/MLKL necroptosis - a disulfiram-based strategy to reverse paclitaxel resistance in ovarian cancer","","Objective Paclitaxel is a cornerstone first-line therapy for ovarian cancer, but its efficacy is limited by chemoresistance. Disulfiram (DSF), an FDA-approved alcohol-aversion drug, shows promising antitumor activity, yet its effects on paclitaxel sensitivity and the underlying mechanism in ovarian cancer remain unclear. Methods DSF was evaluated as a reversal agent using paclitaxel-resistant and parent cells, dissecting RIPK1/RIPK3/MLKL-regulated necroptosis versus caspase-dependent apoptosis, with in vitro mechanistic validation and resistant xenograft confirmation. Results DSF enhanced paclitaxel chemosensitivity, selectively triggering necroptosis in cells with higher caspase-8 and apoptosis in those with lower caspase-8. Conclusion DSF directly bound AIF and promoted necroptosis activation, supporting AIF-mediated necroptosis as a strategy to overcome chemoresistance with minimal toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-aif-to-trigger-ripksmlkl-necroptosis-a-disulfiram-based-strategy-to-reverse-paclitaxel-resistance-in-ovarian-cancer/356218/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-aif-to-trigger-ripksmlkl-necroptosis-a-disulfiram-based-strategy-to-reverse-paclitaxel-resistance-in-ovarian-cancer/356218.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does disulfiram (DSF) affect paclitaxel resistance in ovarian cancer?","Question",{"text":112,"@type":113},"DSF reverses paclitaxel resistance by improving paclitaxel chemosensitivity and promoting programmed cell death pathways in resistant models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cell death mechanisms does DSF activate, and how is it context-dependent?",{"text":117,"@type":113},"DSF selectively triggers RIPK1/RIPK3/MLKL-regulated necroptosis in paclitaxel-resistant cells with higher caspase-8, while promoting caspase-dependent apoptosis when caspase-8 expression is lower.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of AIF in DSF-induced necroptosis?",{"text":121,"@type":113},"DSF directly binds AIF, enhancing RIPK1/RIPK3/MLKL phosphorylation and necroptosis activation; AIF knockdown suppresses these effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356218,1790161630,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Li etal. Cell Communication and Signaling (2026) 24:492  \n[https://doi.org/10.1186/s12964-026-03029-1](https://doi.org/10.1186/s12964-026-03029-1)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nTargeting AIF to trigger RIPKs/MLKL necroptosis: a disulfiram-based strategy to reverse paclitaxel resistance in ovarian cancer  \nJiaofeng Li1,2†, Wei Zhou1,2†, Hualong Tang1†, Wanglong Zhu1†, Miao He1, Qing Xiong1, Zhengyu Han 1, Xinyue Lin1, Ji Chen1, Xingqiang He3, Mei Chen1, YuhanYang1, Xia Meng1, Liping Ma1, Fengtian Li1*, Jingyi Wang1* and Kun Zhang1,4*  \nAbstract  \nObjective Paclitaxel is a cornerstone first-line therapy for ovarian cancer, but its efficacy is limited by chemoresistance. Disulfiram (DSF), an FDA-approved alcohol-aversion drug, shows promising antitumor activity. However, its impact on paclitaxel sensitivity in ovarian cancer and the underlying mechanism remain unclear. Methods This study identified DSF as a reversal agent of paclitaxel resistance. In vitro, DSF’s chemosensitizing effect was tested on paclitaxel-resistant and parent ovarian cancer cells. Mechanistic investigations involved examining the triggering of RIPK1/RIPK3/MLKL-regulated necroptosis versus caspase-dependent apoptosis, depending on cellular context. RIPK1 was inhibited with Nec-1, and the direct binding to Apoptosis-inducing factor (AIF) was studied, with AIF knockdown used for validation. In vivo studies were conducted using resistant xenograft models to confirm the anticancer efficacy and observe necroptosis markers.  \nResults DSF significantly improved paclitaxel chemosensitivity in vitro. Mechanistically, it selectively triggered necroptosis in paclitaxel-resistant cells with higher caspase-8 expression, while promoting apoptosis in cells with lower caspase-8 expression. RIPK1 inhibition impaired DSF-induced necroptosis and chemosensitization. Furthermore, DSF directly bound to AIF, enhancing RIPK1/RIPK3/MLKL phosphorylation and necroptosis activation; this effect was suppressed by AIF knockdown. Crucially, in vivo studies confirmed that DSF boosted the anticancer efficacy of  \n†Jiaofeng Li, Wei Zhou, Hualong Tang and Wanglong Zhu contributed equally to this work.  \n*Correspondence:  \nFengtian Li[lft549544593@live.com](lft549544593@live.com)[ ](lft549544593@live.com)Jingyi Wang [wjy416h@163.com](wjy416h@163.com)[ ](wjy416h@163.com)Kun Zhang [zhangkunyyo@cmc.edu.cn](zhangkunyyo@cmc.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLi et al. Cell Communication and Signaling (2026) 24:492 Page 2 of 15  \npaclitaxel in resistant models, which was accompanied by upregulation of the necroptosis executor p-MLKL and no observable toxicity.  \nConclusion Our findings not only unveiled a novel mechanistic basis for the repurposing of DSF but also highlighted AIF-mediated necroptosi","cbCaiatqQFsVPGAx","https://ap.wps.com/l/cbCaiatqQFsVPGAx","pdf",9589971,15,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"How does disulfiram (DSF) affect paclitaxel resistance in ovarian cancer?\",\"answer\":\"DSF reverses paclitaxel resistance by improving paclitaxel chemosensitivity and promoting programmed cell death pathways in resistant models.\"},{\"question\":\"Which cell death mechanisms does DSF activate, and how is it context-dependent?\",\"answer\":\"DSF selectively triggers RIPK1/RIPK3/MLKL-regulated necroptosis in paclitaxel-resistant cells with higher caspase-8, while promoting caspase-dependent apoptosis when caspase-8 expression is lower.\"},{\"question\":\"What is the role of AIF in DSF-induced necroptosis?\",\"answer\":\"DSF directly binds AIF, enhancing RIPK1/RIPK3/MLKL phosphorylation and necroptosis activation; AIF knockdown suppresses these effects.\"}]","Targeting AIF to trigger RIPKs/MLKL necroptosis - a disulfiram-based strategy to reverse paclitaxel resistance in ovarian cancer | PDF",1790124124,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6538fae6a065f90eda46b6a74dcd1d70.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9d61f9c0fcaad938a61314f41cc7d96.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/590d0c29442db17fd81276d3adc3a3a5.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/976ec317766d1ed37a021a90a98435b4.webp",980,1306]